INMB

INmune Bio (INMB)

About INmune Bio (INMB)

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

Details

Daily high

$1.22

Daily low

$1.16

Price at open

$1.21

52 Week High

$11.64

52 Week Low

$1.15

Market cap

33.0M

Dividend yield

0.00%

Volume

270,231

Avg. volume

614,233

P/E ratio

-.58

INmune Bio News